American biotech company TRex Bio Inc. in the field of autoimmune and inflammatory diseases plans to raise $133.3 million in an IPO on October 8. This is reported in the TRex press release.
TRex expects to place 8.3 million shares at a price of $14-16 and increase the market value to $439 million. The investors include Eli Lilly&Co., SV Health Investors, Pfizer Ventures, Johnson&Johnson Innovation, Janus Henderson Investors, Alexandria Venture Investments, Delos Capital and Polaris Partners. Eli Lilly is ready to buy out a 19.9% stake.
TRex plans to use the proceeds from the placement to promote the candidate drug TRB-061 for the treatment of atopic dermatitis.
JPMorgan Chase & Co., Evercore Inc., Cantor Fitzgerald, Stifel Financial Corp. and Wedbush PacGrow are acting as organizers of the TRex IPO on the Nasdaq Global Select Market.
TRex can become one of the leaders in terms of growth rates among companies going public in the healthcare sector in the United States. In 2026, biotech and pharmaceutical companies raised $7.6 billion through IPOs (six times more than in 2025) in the United States.
Trex Bio, Inc. is an American biotech company headquartered in San Francisco (California).
Read our Telegram channel "Mergers and Acquisitions. AK&M».
Our channel at MAX is "Mergers and Acquisitions. AK&M».
